


ANDROGENS & THEIR ANTAGONISTS

Dr.Nashwa Abo-Rayah Associate prof. (clinical &experimental pharmacology) Mu'tah University- Faculty of Medicine


Testosterone

- **Testosterone** is the main androgen produced in testis by interstitial cells of Leydig under influence of (LH).
- There are specific androgen receptors (AR) in cytoplasm of target cell.
- •AR: ligand-dependent nuclear transcription factor and member of the steroid hormone nuclear receptor family.
- •Testosterone has androgenic and anabolic activity???


Testosterone Biosynthesis & Metabolism



Physiological effects of testosterone



Regulation of testosterone synthesis & secretion



Testosterone preparations Ester moiety cleaved by tissue esterases following administration to yield active testosterone More lipophilic. Formulation for OCO(CH₂): OCO(CH₂)₅CH₃ **Transdermal Delivery** · Avoids first pass effect Long acting Testosterone Testosterone Esterification cypionate ethanate Parenteral administration (e.g. IM) Oral administration Testosterone 17α Alkylation - Orally bioavailable Rapidly orally absorbed - Less androgenic than testosterone 17α alkylation Low oral bioavailability inhibits hepatic - Increased hepatotoxicity High first pass metabolism catabolism Methyltestosterone

X

Testosterone indications and therapeutic uses

Male hypogonadism

Primary Disease of testes - Sperm & testosterone < normal

LH & FSH > normal (no negative feedback)

Secondary Hypothalamus/ - Sperm & Testosterone < normal

Pituitary Disease - LH & FSH < normal

Symptoms:

In utero - ambiguous sexual organ development

- micropenis at birth

Prepubertal - failure to undergo complete puberty

Adult - Venergy & libido

- infertility

Treatment:

- Testosterone replacement therapy
 - o adolescents at the time of puberty
 - o in symptomatic adult men

Note: Treatment of older men with age-related declines in testosterone levels, but no overt hypogonadal symptoms or underlying hypothalamic/pituitary or testicular disease is controversial.

Goal of treatment:

- to restore testosterone levels to the normal range
 - Serum testosterone levels are monitored for clinical efficacy

Clinical Benefit:

- development/maintenance of secondary sexual characteristics
- Nibido (mediated in part by estradiol)
- muscle strength
- fat-free mass (mediated in part by estradiol)
- \(\bar{\text{bone density (mediated by estradiol)}} \)
- improved mood & cognition (+/-)

Adverse effects:

- Acne
- Increased risk of prostate cancer/benign prostatic hyperplasia
- Worsening of sleep apnea
- Increased cardiovascular disease risk (♥HDL & ♠LDL)
- Increased risk of venous thromboembolic disease
- Erythrocytosis increase in red cell mass (increased risk of VTE)
- Hepatic dysfunction (- 17α alkylated derivatives)
- Suppression of spermatogenesis
 - inhibition of LH production results in reduction of high level endogenous local testicular testosterone known to be required for sperm production


Contraindications:

- Pre-existing Prostate cancer
- High levels of PSA in men at high risk for prostate cancer
- Untreated sleep apnea

Androgens as performance enhancing drugs

- •Anabolic Androgenic Steroids (AASs) –(naturally occurring or synthetic) hormones increase lean body mass and decrease fat mass and are the most frequently used class of performance-enhancing drugs.
- •they can also have significant adverse effects, especially when used incorrectly. Long-term, non-medical uses are linked to heart problems, unwanted physical changes, and aggression.
- •Doping "Doping" refers to the use of banned substances in competitive sports.

ANTI-ANDROGENS



Pharmacological antagonists include:

1. GnRH analogues: e.g leuprolide Higher affinity for GnRH receptor in pituitary than endogenous GnRH.

Administration: SC or IM of leuprolide (DEPOT FORM) every 1-4 months; at first it will stimulate, but then desensitizes GnRH receptor causing ↓ secretion of FSH & LH, so ↓ testosterone secretion in male or estrogen secretion in female.

Indications:

1- palliative treatment of prostate cancer (androgendependent), usually with androgen receptor antagonist 2- ovarian hyperstimulation programs for anovulatory infertility to suppress endogenous Gn production during administration of exogenous Gonadotrophins,

but pure GnRH competitive antagonists like Ganirelix are preferred for this suppression since they act quickly.

Adverse effects:

Prolonged use of GnRH analogues may produce menopausal symptoms, and osteoporosis in females (if used longer than 6 months).

2. Androgen receptor antagonists:

- a. Steroidal:
- 1. Spironolactone: block AR and decreasing testosterone synthesis by inhibiting 17α -hydroxylase. Used for Hirsutism, alopecia, acne
 - Cyproterone: blocks androgen receptors,Used for Hirsutism if spironolactone fails.

Sometimes it is used in prostate cancer palliation

Dianette contains an oestrogen and an anti-androgen. Dianette is used to treat skin conditions such as acne, very oily skin and excessive hair growth in females of reproductive age.

b. Non-steroidal:

- Flutamide: used for palliation of prostate cancer.

Its continued use may lead to ↑ LH secretion which ↑ testosterone synthesis, and may thus cause therapeutic failure.

So usually it is combined with GnRH antagonist or replaced by cyproterone.

- S.E.: loss of libido, impotence, vomiting, gynaecomastia, reversible hepatic dysfunction.
 - **Bicalutamide** has fewer GI side effects; no liver toxicity

3. Synthesis inhibitors:

Ketoconazole: blocks many CYP450 enzymes in gonads for synthesis of Testosterone. Found to be less effective than anti-androgens in prostate cancer. S.E.: gynaecomastia; liver toxicity

4. 5α-reductase inhibitors:

- **Finasteride**: blocks synthesis of Dihydrotestosterone from testosterone in *prostate* and *hair follicles* by inhibiting the enzyme 5α-reductase 2.

Used orally in:

Benign prostatic hyperplasia in elderly

(20% reduction in prostate size after 1 year of use)

Other uses of finasteride are: Male pattern of baldness Hirsutism

- Was not found useful in prostate cancer since 5α-reductase 1 is still intact in other tissues e.g. liver, skin fibroblasts

advantages: less likely to cause ↓ libido or impotence than androgen receptor antagonist

References

Lippincott's Illustrated Review

Pharmacology, 5th edition

Lippincott Williams & Wilkins

Katzung by Anthony Trevor, Bertram Katzung, and Susan Masters . last edition McGraw Hill,

Rang & Dale's Pharmacology: by Humphrey P. Rang ; James M.

Ritter; Rod Flower Churchill Livingstone; 6 edition

THANK YOU